
Top Research Reports for AstraZeneca, RTX & Applied Materials
AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
OCALA, Fla., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- AIM ImmunoTech Inc. ( NYSE American: AIM ) ( "AIM" or the "Company" ) , today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, ...
OCALA, Fla., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- AIM ImmunoTech Inc. ( NYSE:AIM ) ( "AIM" or the "Company" ) , today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, ...
TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
The Vanguard FTSE Developed Markets Index Fund has low fees, a high yield, and excellent diversification.
In the latest trading session, Astrazeneca (AZN) closed at $84.69, marking a +1.03% move from the previous day.
INVO Fertility Inc ( NASDAQ:IVF ) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.
Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.
JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.
The procedure is often not fully covered by insurance - if covered at all - and the costs for accessing it can cost around $20,000 or more per cycle.
○ Efficacy: ORR of 68% with lasme-cel Process 2 ( n=22 ) , 83% at RP2D ( n=12 ) and 100% in the target Phase 2 population ( n=9 ) ○ Safety: in Phase 1 ( n=40 ) , lasme-cel was generally well-tolerated ( including 1 case of grade 2 IEC-HS which resolved )
○ Efficacy: ORR of 68% with lasme-cel Process 2 ( n=22 ) , 83% at RP2D ( n=12 ) and 100% in the target Phase 2 population ...
The program will sell Xofluza through three pharmacies with a $50 cash pay option, which is 70% lower than the pill's current list price before insurance.
Merck & Co. Inc. ( NYSE:MRK ) announced data from the Phase 3 KEYNOTE-B96 trial ( ENGOT-ov65 ) of Keytruda ( pembrolizumab ) in combination with chemotherapy ( paclitaxel ) with or without Roche Holdings AG's ( OTC:RHHBY ) Avastin ( bevacizumab ) .
These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.
Trade war jitters rise, but ETFs like MSOS, SILJ, SGDJ, BBC, WISE & CTEX shine on solid fundamentals, offering either safe havens or growth potential.
Eli Lilly and Co ( NYSE:LLY ) on Wednesday shared topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels. LLY is gathering positive momentum. See what is happening here.
Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ...
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
Shah Capital is reportedly pressing Novavax Inc. ( NASDAQ:NVAX ) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. The hedge fund holds a 7.2% stake and is the company's second-largest shareholder.
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.
Escalating U.S.-China trade tensions are shaking global markets, prompting investors to eye UK ETFs like EWU as a potential safe haven.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Trump is set to announce the agreement with AstraZeneca on Friday, after striking a similar deal with Pfizer late last month.
President Donald Trump is reportedly set to announce a new agreement with AstraZeneca Plc ( NASDAQ:AZN ) designed to reduce prescription drug costs for Americans. A White House official told MSNBC that the announcement is expected to come from the Oval Office later Friday afternoon.
UK ministers are preparing to increase the amount the National Health Service pays pharmaceutical firms for medicines by up to 25%, following weeks of intensive discussions with the Trump administration and drugmakers.
AstraZeneca Plc ( NASDAQ:AZN ) on Thursday said it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500 million to support the enhanced manufacturing capability of a broader range of medicines, including cancer treatments.
Prescription savings platform GoodRx Holdings Inc. ( NASDAQ:GDRX ) is reportedly joining the so-called TrumpRx website, signaling an initiative expansion beyond pharmaceutical manufacturers' direct discount programs.
In the current session, the stock is trading at $86.19, after a 0.94% increase. Over the past month, AstraZeneca Inc. ( NASDAQ:AZN ) stock increased by 6.27%, and in the past year, by 11.42%.
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
These two up-and-coming tech stocks just might make investors more money over the next decade than Nvidia will.
Investors are more hopeful about the pharma industry's chances of mitigating US threats ...
Tracking the financial-market trades of members of Congress might be the ultimate investor edge-especially with one AI stock in Nancy Pelosi's portfolio now up over 200% since she bought in.
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
PITTSBURGH, Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- MetasTx, an early-stage biotech originally founded in New Jersey and now headquartered in Pittsburgh, announced progress on its two-part precision oncology platform designed to identify and treat men with prostate cancer who are most likely to ...
QBTS ramps up commercial quantum deployments with its new Advantage2 system, but investors remain wary.
On Tuesday, AstraZeneca Plc ( NASDAQ:AZN ) released high-level results from the Bax24 Phase 3 trial to evaluate the safety, tolerability, and the effect of 2mg baxdrostat versus placebo.
TMO joins AstraZeneca's BioVentureHub to boost R&D, innovation and life science access.
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.